AssetMark’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$135 Buy
+8
New +$120 ﹤0.01% 3665
2026
Q1
– Sell
-44
Closed -$770 – 3584
2025
Q4
$770 Sell
44
-29,822
-100% -$561K ﹤0.01% 3008
2025
Q3
$617K Sell
29,866
-1,218
-4% -$29.5K ﹤0.01% 1065
2025
Q2
$661K Buy
+31,084
New +$709K ﹤0.01% 999

Other funds holding SMMT

AssetMark's SMMT Position: Q3 2026 in Review

AssetMark opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 8 shares worth $135. The stake represents ﹤0.01% of the portfolio and ranks #3665 among its holdings. This is a return to the name: AssetMark previously reported a position in SMMT as recently as Q4 2025.

AssetMark first reported a position in SMMT in Q2 2025 and has held it in 4 quarters since. The position peaked at $661K in Q2 2025. 211 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • AssetMark held 8 shares of Summit Therapeutics worth $135 as of Q3 2026.
  • Summit Therapeutics was a new AssetMark position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3665 holding.
  • AssetMark first reported a position in Summit Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • AssetMark's Summit Therapeutics position peaked at $661K in Q2 2025.
  • 211 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.